Drug Profile
ANX 007
Alternative Names: Anti-C1q therapy - Annexon; ANX-007Latest Information Update: 29 Mar 2024
Price :
$50
*
At a glance
- Originator Annexon
- Class Antiglaucomas; Eye disorder therapies; Fab fragments; Monoclonal antibodies
- Mechanism of Action Complement C1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dry macular degeneration
- No development reported Open-angle glaucoma
Most Recent Events
- 26 Mar 2024 Annexon plans a phase III ARROW trial for Dry age related macular degeneration in the second half of 2024
- 20 Dec 2023 Annexon plans a phase III ARCHER-II trial for Dry age related macular degeneration in mid-2024
- 24 Oct 2023 ANX 007 receives Priority Medicine (PRIME) status for Dry age-related macular degeneration in Europe